NEW YORK, Jan. 28, 2014 /PRNewswire/ -- S&P Capital IQ announced today that it has commenced Standard & Poor's Factual Stock Report coverage on OxySure Systems, Inc.

OxySure Systems, Inc. (OTCQB:OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company has developed a safe and easy-to-use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which is designed to make the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems.

OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need. These areas include public and private places and settings where medical emergencies can occur; individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military or other environments deemed to be immediately dangerous to life or health.

The company's technology, process and methodologies involve the creation of USP oxygen from two dry, inert powders. OxySure believes that other available chemical oxygen generating technologies contain hazards that make them commercially unviable for broad-based emergency use by lay rescuers or the general public.  The company's launch product is the OxySure Model 615 portable emergency oxygen system. OxySure believes that the OxySure Model 615 is the only product on the market (as of November 2013) that can be safely pre-positioned in public and private venues for emergency administration of medical oxygen by lay persons, without the need for training.

On January 2, 2014, OxySure announced that it had closed a $750,000 private placement with accredited institutional investors. Pursuant to a purchase agreement with the investors, OxySure sold units which included shares of Series B convertible preferred stock and warrants to purchase common shares of the company. The net proceeds to the company from the offering, after deducting various expenses, were approximately $677,000, to be used primarily for general corporate purposes.

OxySure Systems, Inc. was formed in January 2004 and is based in Frisco, Texas.

S&P Capital IQ's Factual Stock Report coverage on OxySure Systems, Inc will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P Capital IQ research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. Please visit www.oxysure.com for additional information.

About S&P Capital IQ's Factual Stock Reports

Currently profiling approximately 500 issuers, Standard & Poor's Factual Stock Reports, produced by S&P Capital IQ, increase market awareness of issuers in the investment community with insightful commentary and key statistics and information.  Standard & Poor's Factual Stock Reports provide factual research coverage about company fundamentals and business prospects, thereby enabling information about covered companies to reach a wide investor audience of Buy and Sell-side investors. Updated weekly with the latest pricing, trading volume, and other data, the reports include recent developments, a financial review, key operating information, industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, performance charts, business summary, fundamental data, and news. Because coverage of these reports is underwritten by the issuer, S&P Capital IQ does not offer investment opinions concerning the advisability of investing in these stocks.

Standard & Poor's Factual Stock Reports are produced separately from any other analytic activity of S&P Capital IQ or related organizations.  S&P Capital IQ does not trade on its own account.

About S&P Capital IQ

S&P Capital IQ, a part of McGraw Hill Financial, is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. Evaluated pricing is prepared by Standard & Poor's Securities Evaluations, Inc., a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission.  In the United States, research reports are prepared by Standard & Poor's Investment Advisory Services LLC, a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. S&P Capital IQ provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. For more information visit: www.spcapitaliq.com.

SOURCE S&P Capital IQ